Ipsen Announces the Availability of the Newly Designed Delivery System for Somatuline® Autogel® (lanreotide injection)
Ipsen Biopharmaceuticals Canada Inc. today announced the availability of a new delivery system for Somatuline® Autogel® (lanreotide injection) 60, 90, and 120 mg. The new pre-filled syringe is now available for Canadian patients and includes updated features designed to help make it easier for healthcare providers and patients to administer the injection. Somatuline® Autogel® (lanreotide injection) is approved for the treatment of enteropancreatic neuroendocrine tumours (NETs) in adult patients with Grade 1 or a subset of Grade 2 (equivalent to Ki67<10%) unresectable, locally advanced or metastatic disease, to delay progression;i treatment of adult patients with carcinoid syndrome; long-term treatment of patients with acromegaly due to pituitary tumours who have had an inadequate response to or cannot be treated with surgery or radiotherapy.ii